NCT07515625 2026-04-07
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
46 trialsNCT05427487 2026-03-25
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Phase 1 Recruiting
NCT07492615 2026-03-25
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Recruiting
NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT05161572 2025-06-18
NeoRacing
Fudan University
Phase 2 Terminated
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06977061 2025-05-16
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Second Affiliated Hospital of Nanchang University
Phase 2/3 Not yet recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06748508 2024-12-27
FDZL-GC003
Fudan University
Phase 2 Not yet recruiting
NCT06697366 2024-11-20
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06564298 2024-08-28
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06555471 2024-08-15
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06499610 2024-07-12
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06454435 2024-06-12
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06383559 2024-04-25
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05918094 2024-01-26
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT06091423 2023-11-30
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06123455 2023-11-08
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
Phase 2 Unknown
NCT06094868 2023-10-23
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT06046963 2023-09-21
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05795296 2023-08-30
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT05982301 2023-08-08
Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05928897 2023-07-05
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT05640609 2023-05-16
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
West China Hospital
Phase 1/2 Recruiting
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05720533 2023-02-09
Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05594381 2022-10-26
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05527821 2022-09-06
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT05204173 2022-01-24
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Unknown
NCT04982939 2021-08-31
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05002686 2021-08-24
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Ruijin Hospital
Phase 2/3 Unknown
NCT04781413 2021-03-04
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Ruijin Hospital
Phase 1/2 Unknown
NCT04567069 2020-09-28
Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
The Second Hospital of Shandong University
Phase 1/2 Unknown
NCT04263870 2020-02-11
CTSCAPOXSEA
Sichuan University
Phase 2 Unknown
NCT04065282 2020-02-10
The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown